Erivedge (vismodegib) is a small molecule pharmaceutical. Vismodegib was first approved as Erivedge on 2012-01-30. It is used to treat skin neoplasms in the USA. It has been approved in Europe to treat basal cell carcinoma. The pharmaceutical is active against smoothened homolog. In addition, it is known to target Soluble cytochrome b562. Erivedge's patents are valid until 2028-12-15 (FDA).
|Indication||basal cell carcinoma, skin neoplasms|
|Drug Class||Hedgehog signaling inhibitors|